HbA1c as a screening tool for detection of type 2 diabetes: A systematic review

Bennett, C.M., Gao, M. and Dharmage, S.C. 2007, HbA1c as a screening tool for detection of type 2 diabetes: A systematic review, Diabetic medicine, vol. 24, no. 4, pp. 333-343.


Title HbA1c as a screening tool for detection of type 2 diabetes: A systematic review
Author(s) Bennett, C.M.
Gao, M.
Dharmage, S.C.
Journal name Diabetic medicine
Volume number 24
Issue number 4
Start page 333
End page 343
Publisher Wiley - Blackwell Publishing
Place of publication Oxford, England
Publication date 2007-04
ISSN 0742-3071
1464-5491
Keyword(s) diabetes
diagnosis screening
HbA1c
systematic review
Summary Aim: To assess the validity of glycated haemoglobin A1c (HbA1c) as a screening tool for early detection of Type 2 diabetes.

Methods: Systematic review of primary cross-sectional studies of the accuracy of HbA1c for the detection of Type 2 diabetes using the oral glucose tolerance test as the reference standard and fasting plasma glucose as a comparison.

Results: Nine studies met the inclusion criteria. At certain cut-off points, HbA1c has slightly lower sensitivity than fasting plasma glucose (FPG) in detecting diabetes, but slightly higher specificity. For HbA1c at a Diabetes Control and Complications Trial and UK Prospective Diabetes Study comparable cut-off point of ≥ 6.1%, the sensitivity ranged from 78 to 81% and specificity 79 to 84%. For FPG at a cut-off point of ≥ 6.1 mmol/l, the sensitivity ranged from 48 to 64% and specificity from 94 to 98%. Both HbA1c and FPG have low sensitivity for the detection of impaired glucose tolerance (around 50%).

Conclusions: HbA1c and FPG are equally effective screening tools for the detection of Type 2 diabetes. The HbA1c cut-off point of > 6.1% was the recommended optimum cut-off point for HbA1c in most reviewed studies; however, there is an argument for population-specific cut-off points as optimum cut-offs vary by ethnic group, age, gender and population prevalence of diabetes. Previous studies have demonstrated that HbA1c has less intra-individual variation and better predicts both micro- and macrovascular complications. Although the current cost of HbA1c is higher than FPG, the additional benefits in predicting costly preventable clinical complications may make this a cost-effective choice.
Language eng
Field of Research 110399 Clinical Sciences not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30021869

Document type: Journal Article
Collections: School of Health and Social Development
Higher Education Research Group
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 165 times in TR Web of Science
Scopus Citation Count Cited 198 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 515 Abstract Views  -  Detailed Statistics
Created: Mon, 18 Jan 2010, 11:01:05 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.